Back to Search Start Over

Attributable Cost and Length of Stay Associated with Nosocomial Gram-Negative Bacterial Cultures.

Authors :
Nelson RE
Stevens VW
Jones M
Khader K
Schweizer ML
Perencevich EN
Rubin MA
Samore MH
Source :
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2018 Oct 24; Vol. 62 (11). Date of Electronic Publication: 2018 Oct 24 (Print Publication: 2018).
Publication Year :
2018

Abstract

Few studies have estimated the excess inpatient costs due to nosocomial cultures of Gram-negative bacteria (GNB), and those that do are often subject to time-dependent bias. Our objective was to generate estimates of the attributable costs of the underlying infections associated with nosocomial cultures by using a unique inpatient cost data set from the U.S. Department of Veterans Affairs that allowed us to reduce time-dependent bias. Our study included data from inpatient admissions between 1 October 2007 and 30 November 2010. Nosocomial GNB-positive cultures were defined as clinical cultures positive for Acinetobacter , Pseudomonas , or Enterobacteriaceae between 48 h after admission and discharge. Positive cultures were further classified by site and level of resistance. We conducted analyses using both a conventional approach and an approach aimed at reducing the impact of time-dependent bias. In both instances, we used multivariable generalized linear models to compare the inpatient costs and length of stay for patients with and without a nosocomial GNB culture. Of the 404,652 patients included in the conventional analysis, 12,356 had a nosocomial GNB-positive culture. The excess costs of nosocomial GNB-positive cultures were significant, regardless of specific pathogen, site, or resistance level. Estimates generated using the conventional analysis approach were 32.0% to 131.2% greater than those generated using the approach to reduce time-dependent bias. These results are important because they underscore the large financial burden attributable to these infections and provide a baseline that can be used to assess the impact of improvements in infection control.<br /> (Copyright © 2018 American Society for Microbiology.)

Details

Language :
English
ISSN :
1098-6596
Volume :
62
Issue :
11
Database :
MEDLINE
Journal :
Antimicrobial agents and chemotherapy
Publication Type :
Academic Journal
Accession number :
30150480
Full Text :
https://doi.org/10.1128/AAC.00462-18